Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allegrini

Showing results (661-670 of 719) with videos related to

Pageof 72
Sort By:
Geophysical Research Letters|July 21, 2022
Closed Fluxtubes and Dispersive Proton Conics at Jupiter's Polar CapJ R Szalay, G Clark, G Livadiotis, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
Angiogenesis|March 3, 2012
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersGiacomo Allegrini, Teresa Di Desidero, Maria Teresa Barletta, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Genetic contributions of noncognitive skills to academic developmentMargherita Malanchini, Andrea G Allegrini, Michel G Nivard, et al.
JAMA Oncology|June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 TrialJavier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Nature Human Behaviour|August 26, 2024
Genetic associations between non-cognitive skills and academic achievement over developmentMargherita Malanchini, Andrea G Allegrini, Michel G Nivard, et al.
Journal of Molecular and Cellular Cardiology|May 11, 2021
Piezo1 and BK<sub>Ca</sub> channels in human atrial fibroblasts: Interplay and remodelling in atrial fibrillationDorothee Jakob, Alexander Klesen, Benoit Allegrini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trialChiara Cremolini, Federica Marmorino, Francesca Bergamo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Pageof 72

Showing results (661-670 of 719) with videos related to

Sort By:
Pageof 72
Geophysical Research Letters|July 21, 2022
Closed Fluxtubes and Dispersive Proton Conics at Jupiter's Polar CapJ R Szalay, G Clark, G Livadiotis, et al.
BMC Cancer|June 11, 2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO groupChiara Cremolini, Federica Marmorino, Fotios Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
Angiogenesis|March 3, 2012
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersGiacomo Allegrini, Teresa Di Desidero, Maria Teresa Barletta, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Genetic contributions of noncognitive skills to academic developmentMargherita Malanchini, Andrea G Allegrini, Michel G Nivard, et al.
JAMA Oncology|June 26, 2020
Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 TrialJavier Cortés, Véronique Diéras, Sylvie Lorenzen, et al.
Nature Human Behaviour|August 26, 2024
Genetic associations between non-cognitive skills and academic achievement over developmentMargherita Malanchini, Andrea G Allegrini, Michel G Nivard, et al.
Journal of Molecular and Cellular Cardiology|May 11, 2021
Piezo1 and BK<sub>Ca</sub> channels in human atrial fibroblasts: Interplay and remodelling in atrial fibrillationDorothee Jakob, Alexander Klesen, Benoit Allegrini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 9, 2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trialChiara Cremolini, Federica Marmorino, Francesca Bergamo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Pageof 72